## Ian R Rifkin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3676145/publications.pdf Version: 2024-02-01



IAN P RIEKIN

#	Article	IF	CITATIONS
1	Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 2002, 416, 603-607.	13.7	1,767
2	RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. Journal of Experimental Medicine, 2005, 202, 1171-1177.	4.2	730
3	Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes. Journal of Experimental Medicine, 2004, 199, 1631-1640.	4.2	476
4	Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunological Reviews, 2005, 204, 27-42.	2.8	368
5	Immunologically Active Autoantigens: The Role of Toll-Like Receptors in the Development of Chronic Inflammatory Disease. Annual Review of Immunology, 2007, 25, 419-441.	9.5	357
6	Murine Dendritic Cell Type I IFN Production Induced by Human IgG-RNA Immune Complexes Is IFN Regulatory Factor (IRF)5 and IRF7 Dependent and Is Required for IL-6 Production. Journal of Immunology, 2007, 178, 6876-6885.	0.4	157
7	Impaired Clearance of Apoptotic Cells Promotes Synergy between Atherogenesis and Autoimmune Disease. Journal of Experimental Medicine, 2004, 199, 1121-1131.	4.2	155
8	Poly(I:C) Drives Type I IFN- and TGFÎ <sup>2</sup> -Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis. Journal of Investigative Dermatology, 2010, 130, 2583-2593.	0.3	121
9	Murine B Cell Response to TLR7 Ligands Depends on an IFN-β Feedback Loop. Journal of Immunology, 2009, 183, 1569-1576.	0.4	119
10	Requirement for DNA CpG Content in TLR9-Dependent Dendritic Cell Activation Induced by DNA-Containing Immune Complexes. Journal of Immunology, 2009, 183, 3109-3117.	0.4	104
11	IFN Regulatory Factor 5 Is Required for Disease Development in the <i>FcγRIIBâ^'/â^'Yaa</i> and <i>FcγRIIBâ^'/â^'</i> Mouse Models of Systemic Lupus Erythematosus. Journal of Immunology, 2010, 184, 796-806.	0.4	91
12	Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus. Joint Bone Spine, 2011, 78, 124-130.	0.8	89
13	Simvastatin Treatment Ameliorates Autoimmune Disease Associated with Accelerated Atherosclerosis in a Murine Lupus Model. Journal of Immunology, 2006, 177, 3028-3034.	0.4	88
14	The Peroxisome Proliferator-Activated Receptor Î <sup>3</sup> Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin. Journal of Immunology, 2009, 182, 340-346.	0.4	86
15	Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses. Immunity, 2017, 46, 106-119.	6.6	84
16	Gene Expression during the Generation and Activation of Mouse Neutrophils: Implication of Novel Functional and Regulatory Pathways. PLoS ONE, 2014, 9, e108553.	1.1	83
17	Immune Complexes Present in the Sera of Autoimmune Mice Activate Rheumatoid Factor B Cells. Journal of Immunology, 2000, 165, 1626-1633.	0.4	72
18	Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. European Journal of Immunology, 1996, 26, 1260-1265.	1.6	66

Ian R Rifkin

#	Article	lF	CITATIONS
19	Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. International Immunology, 2013, 25, 295-306.	1.8	55
20	Toll-Like Receptors and Activation of Autoreactive B Cells. , 2002, 6, 105-122.		53
21	IRF5 Deficiency Ameliorates Lupus but Promotes Atherosclerosis and Metabolic Dysfunction in a Mouse Model of Lupus-Associated Atherosclerosis. Journal of Immunology, 2015, 194, 1467-1479.	0.4	50
22	TLR4 Ligands Induce IFN-α Production by Mouse Conventional Dendritic Cells and Human Monocytes after IFN-β Priming. Journal of Immunology, 2009, 182, 820-828.	0.4	49
23	DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo. Arthritis Research and Therapy, 2009, 11, R79.	1.6	48
24	The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. International Journal for Parasitology, 2015, 45, 203-207.	1.3	45
25	c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Scientific Reports, 2019, 9, 20257.	1.6	40
26	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. Journal of Endotoxin Research, 2004, 10, 247-251.	2.5	36
27	Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis and Rheumatology, 2015, 67, 3146-3157.	2.9	36
28	Successful Control of Hyperparathyroidism in Patients on Continuous Ambulatory Peritoneal Dialysis Using Magnesium Carbonate and Calcium Carbonate as Phosphate Binders. Nephron, 1993, 63, 379-383.	0.9	34
29	TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects. Journal of Experimental Medicine, 2017, 214, 1297-1311.	4.2	33
30	Interferon Regulatory Factor-5 Deficiency Ameliorates Disease Severity in the MRL/lpr Mouse Model of Lupus in the Absence of a Mutation in DOCK2. PLoS ONE, 2014, 9, e103478.	1.1	26
31	Peroxisome proliferatorâ€activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology, 2014, 142, 363-373.	2.0	25
32	The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheumatic Disease Clinics of North America, 2004, 30, 559-574.	0.8	24
33	Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. ELife, 2020, 9, .	2.8	24
34	T-bet: The Toll-bridge to class-switch recombination?. Nature Immunology, 2003, 4, 650-652.	7.0	22
35	Lupus Nephritis. Seminars in Nephrology, 2006, 26, 95-104.	0.6	20
36	Role for interferon regulatory factors in autoimmunity. Joint Bone Spine, 2010, 77, 525-531.	0.8	18

IAN R RIFKIN

#	Article	IF	CITATIONS
37	The Effect of Mycophenolate Mofetil on Disease Development in the gld.apoEâ^'/â^' Mouse Model of Accelerated Atherosclerosis and Systemic Lupus Erythematosus. PLoS ONE, 2013, 8, e61042.	1.1	18
38	DNA and RNA autoantigens as autoadjuvants. Journal of Endotoxin Research, 2006, 12, 379-384.	2.5	16
39	Inhibition of Type 4 Cyclic Nucleotide Phosphodiesterase Blocks Intracellular TLR Signaling in Chronic Lymphocytic Leukemia and Normal Hematopoietic Cells. Journal of Immunology, 2015, 194, 101-112.	0.4	13
40	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Frontiers in Immunology, 2021, 12, 614676.	2.2	13
41	Cp <scp>GB DNA</scp> activates dermal macrophages and specifically recruits inflammatory monocytes into the skin. Experimental Dermatology, 2015, 24, 133-139.	1.4	10
42	Monoallelic IRF5 deficiency in B cells prevents murine lupus. JCI Insight, 2021, 6, .	2.3	5
43	Evaluating the Role of Nucleic Acid Antigens in Murine Models of Systemic Lupus Erythematosus. Methods in Molecular Biology, 2014, 1169, 143-158.	0.4	3
44	A 57-Year-Old Woman With Recently Diagnosed SLE, Proteinuria, and Microhematuria. American Journal of Kidney Diseases, 2006, 48, 1004-1008.	2.1	2
45	PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells. Blood, 2012, 120, 1774-1774.	0.6	2
46	B Cells and Dendritic Cells from Vκ8 Light Chain Transgenic Mice Activate MRL- <i>lpr/gld</i> CD4+ T Cells. Journal of Immunology, 2006, 177, 45-52.	0.4	1
47	Implication de la famille des facteurs de transcription IRF dans l'auto-immunité. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 556-562.	0.0	0
48	Implication des Toll-like récepteurs dans les maladies auto-immunesÂ: exemple du lupus érythémateux	0.0	0

systémique. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 18-25. 48